Fibric Acids

"Fibric Acids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that either share the structure of fibric acid in their molecular arrangement or are considered variants of the fibric acid structure.

Descriptor ID

D058607

MeSH Number(s)

D02.241.081.160.700.500

D02.355.726.305

D02.755.654.305

Concept/Terms

Fibric Acids

Fibrates

Below are MeSH descriptors whose meaning is more general than "Fibric Acids".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Carboxylic Acids [D02.241]
Acids, Acyclic [D02.241.081]
Butyric Acids [D02.241.081.160]
Isobutyric Acids [D02.241.081.160.700]
Fibric Acids [D02.241.081.160.700.500]
Ethers [D02.355]
Phenyl Ethers [D02.355.726]
Fibric Acids [D02.355.726.305]
Phenols [D02.755]
Phenyl Ethers [D02.755.654]
Fibric Acids [D02.755.654.305]

Below are MeSH descriptors whose meaning is related to "Fibric Acids".

Below are MeSH descriptors whose meaning is more specific than "Fibric Acids".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Fibric Acids" by people in Harvard Catalyst Profiles by year, and whether "Fibric Acids" was a major or minor topic of these publication.

Bar chart showing 12 publications over 8 distinct years, with a maximum of 4 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2011	0	1	1
2012	1	1	2
2013	1	0	1
2015	1	0	1
2017	1	0	1
2018	0	1	1
2019	1	0	1
2021	2	2	4

Below are the most recent publications written about "Fibric Acids" by people in Profiles.

Impact of concomitant fibrates on immunotherapy outcomes for advanced non-small cell lung cancer. Cancer Med. 2023 01; 12(1):358-367.

View in: PubMed
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 10 19; 78(16):1635-1654.

View in: PubMed
Physician variation in the de-adoption of ineffective statin and fibrate therapy. Health Serv Res. 2021 10; 56(5):919-931.

View in: PubMed
Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease. Clin Chem. 2021 01 08; 67(1):183-196.

View in: PubMed
Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies. Curr Med Chem. 2021; 28(36):7427-7445.

View in: PubMed
Toxic Myopathies. Continuum (Minneap Minn). 2019 Dec; 25(6):1712-1731.

View in: PubMed
Lipid-Lowering Medications Are Associated with Lower Risk of Retinopathy and Ophthalmic Interventions among United States Patients with Diabetes. Am J Ophthalmol. 2019 11; 207:378-384.

View in: PubMed
PPARa-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling. J Pharm Pharmacol. 2018 Dec; 70(12):1630-1642.

View in: PubMed
Lipid-Lowering Agents and High HDL (High-Density Lipoprotein) Are Inversely Associated With Intracranial Aneurysm Rupture. Stroke. 2018 05; 49(5):1148-1154.

View in: PubMed
Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med. 2017 Feb 03; 15(1):22.

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

JAMA
Atherosclerosis
J Am Coll Cardiol
Health Serv Res
EMBO Mol Med
Curr Pharm Des
Continuum (Minneap Minn)
BMC Med
Ann Clin Psychiatry
Am J Physiol Endocrinol Metab